On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.
Pearce IP BioBlast®: w/e 09 April 2021
06 April 2021 | PlantForm announced it has reached a collaborative research and development agreement with Bio-Manguinhos/Fiocruz to develop a...